Clinicians' views on introducing epidermal growth factor receptor testing in New Zealand

Asia-Pacific Journal of Clinical Oncology

Volumn 9, Issue 3, 2013, Pages 249-256

  Batten, Lesley S ^a   Winter, Helen S ^b   Hardie, Claire L ^b   Holdaway, Maureen A ^a  

^a MASSEY UNIVERSITY   (New Zealand)

^b MidCentral District Health Board   (New Zealand)

Author keywords

Epidermal growth factor receptor; New Zealand; Non small cell lung cancer; Survey

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CULTURAL SENSITIVITY; FEMALE; GENE MUTATION; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH SERVICE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; NEW ZEALAND; PATIENT CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUESTIONNAIRE; TREATMENT RESPONSE;

EPIDERMAL GROWTH FACTOR RECEPTOR; NEW ZEALAND; NON-SMALL-CELL LUNG CANCER; SURVEY;

ATTITUDE OF HEALTH PERSONNEL; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LUNG NEOPLASMS; MALE; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84882624609     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12012     Document Type: Article

References (20)

1. Ministry of Health. Cancer: New Registrations and Deaths 2008. Ministry of Health, Wellington 2011.
2. Ministry of Health. Cancer: New Registrations and Deaths 2005: Revised Edition. Ministry of Health, Wellington 2009.
3. Stevens W, Stevens G, Kolbe J, Cox B. Management of stages I and II non-small-cell lung cancer in a New Zealand study: divergence from international practice and recommendations. Inter Med J 2008; 38: 758-768.
4. Stevens W, Stevens G, Kolbe J, Cox B. Varied routes of entry into secondary care and delays in the management of lung cancer in New Zealand. Asia Pac J Clin Oncol 2008; 4: 71-122.
5. Robson B, Purdie G, Cormack D. Unequal Impact: Maori and Non-Maori Cancer Statistics 1996-2001. Ministry of Health, Wellington 2006.
6. Stevens W, Stevens G, Kolbe J, Cox B. Ethnic differences in the management of lung cancer in New Zealand. J Thorac Oncol 2008; 3: 237-244.
7. Zhou W, Christiani DC. East meets west: ethnic differences in epidemiology and clinical behaviours of lung cancer between East Asians and Caucasians. Chin J Cancer 2011; 30: 287-292.
8. Pharmaceutical Management Agency. Pharmac. Pharmaceutical Schedule 2012. [Cited 25 August 2012.) Available from URL: http://www.pharmac.govt.nz/2012/03/28/sched.pdf
9. National Lung Cancer Working Group. Standards of Service Provision for Lung Cancer Patients in New Zealand. Ministry of Health, Wellington 2011.
10. Cadranel J, Zalcman G, Sequist L. Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. Eur Respir J 2011; 37: 183-193.
11. National Institute for Health and Clinical Excellence. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. NICE Technology Appraisal Guidance 192; 2010. [Cited 22 Aug 2012.] Available from URL: http://www.nice.org.uk/TA192.
12. Jackman DM, Miller VA, Cioffredi L-A etal. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15: 5267-5273.
13. Mok TS, Wu YL, Thongprasert S etal. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
14. Maemondo M, Inoue A, Kobayashi K etal. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
15. Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012; 13: 107-114
16. Riely G, Narks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6: 201-205.
17. Soda M, Choi Y, Enomoto M etal. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
18. Olaussen K, Dunant A, Fouret P etal. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
19. Ceppi P, Volante M, Novello I etal. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17:1818-1825.
20. Cunningham E, Cameron V, Evans J, Irvine V, Pitama S, Robertson P. The development of guidelines for handing samples and specimens collected for research involving Maori. N Z Med J 2007; 120 (1264). [Cited 22 Aug 2012 Available from: http://www.nzma.org.nz/journal/120-1264/2785.